Actuate Cash Flow Coverage Ratios from 2010 to 2026
| ACTU Stock | 4.41 0.09 2.08% |
Cash Flow Coverage Ratios | First Reported 2010-12-31 | Previous Quarter (39.54) | Current Value (41.52) | Quarterly Volatility 1.18438772 |
Check Actuate Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Actuate Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 191.9 K, Interest Income of 220.7 K or Depreciation And Amortization of 2.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.4 K. Actuate financial statements analysis is a perfect complement when working with Actuate Therapeutics Valuation or Volatility modules.
Actuate | Cash Flow Coverage Ratios | Build AI portfolio with Actuate Stock |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Actuate Stock Analysis
When running Actuate Therapeutics' price analysis, check to measure Actuate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actuate Therapeutics is operating at the current time. Most of Actuate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Actuate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actuate Therapeutics' price. Additionally, you may evaluate how the addition of Actuate Therapeutics to your portfolios can decrease your overall portfolio volatility.